Mekinist
Active Ingredient(s): Trametinib Dimethyl SulfoxideFDA Approved: * May 29, 2013
Pharm Company: * GLAXOSMITHKLINE LLC
Category: Cancer
Trametinib (trade name Mekinist & Meqsel both by Novartis ) is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity.[1]It inhibits MEK1 and MEK2.[1] Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial. In this mutation, the amino acid valine (V) at position 600 within the BRAF protein has become replaced by glutamic acid (E) making the mutant BRAF protein constitutively active.&a... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Mekinist .5 mg Oral Tablet, Film Coated
NDC: 0078-0666
Labeler:
Novartis Pharmaceuticals Corporation
Mekinist .5 mg Oral Tablet, Film Coated
NDC: 0078-1105
Labeler:
Novartis Pharmaceuticals Corporation
Mekinist .05 mg/ml Oral Powder, for Solution
NDC: 0078-1161
Labeler:
Novartis Pharmaceuticals Corporation
Mekinist 2 mg (As Trametinib Dimethyl Sulfoxide 2.254 mg) Oral Tablet
NDC: 0173-0848
Labeler:
Glaxosmithkline LLC
Mekinist 0.5 mg (As Trametinib Dimethyl Sulfoxide 0.5635 mg) Oral Tablet
NDC: 0173-0849
Labeler:
Glaxosmithkline LLC
Mekinist 1 mg (As 1.127 Trametinib Dimethyl Sulfoxide mg) Oral Tablet
NDC: 0173-0858
Labeler:
Glaxosmithkline LLC
